Sarah Hartz
Dr. Sarah Hartz is a professor of psychiatry at the Washington University School of Medicine in St. Louis, known for her research on Alzheimer's disease and its treatments. She recently gained attention for leading a study that estimates how long patients with mild cognitive decline might maintain their independence when treated with new Alzheimer’s drugs, specifically lecanemab and donanemab.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 2 | 8.00 | 0.04% | +10% | 331,002,651 | 133,006 | $21,000,000 | 8,438$ |
| Totals | 2 | 331,002,651 | 133,006 | $21,000,000 | 8,438$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Senior author Sarah Hartz, MD, PhD, a professor of psychiatry at WashU Medicine, explained the significance of the study's findings.
8
United States:
Dr. Sarah Hartz is the lead author of a new study estimating how long people might continue to live independently after beginning treatment for Alzheimer’s.
8